Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF.
Jhund PS, Ponikowski P, Docherty KF, Gasparyan SB, Böhm M, Chiang CE, Desai AS, Howlett J, Kitakaze M, Petrie MC, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Sabatine MS, Solomon SD, McMurray JJV. Jhund PS, et al. Among authors: verma s. Circulation. 2021 May 18;143(20):1962-1972. doi: 10.1161/CIRCULATIONAHA.121.053659. Epub 2021 Apr 9. Circulation. 2021. PMID: 33832352 Free PMC article.
Mechanical circulatory assistance: state of art.
Delgado DH, Rao V, Ross HJ, Verma S, Smedira NG. Delgado DH, et al. Among authors: verma s. Circulation. 2002 Oct 15;106(16):2046-50. doi: 10.1161/01.cir.0000035281.97319.a2. Circulation. 2002. PMID: 12379571 No abstract available.
Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus.
Connelly KA, Yan AT, Leiter LA, Bhatt DL, Verma S. Connelly KA, et al. Among authors: verma s. Circulation. 2015 Dec 15;132(24):2345-50. doi: 10.1161/CIRCULATIONAHA.115.015946. Circulation. 2015. PMID: 26667098 Review. No abstract available.
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.
Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; EMPEROR Trials Program. Butler J, et al. Among authors: verma s. Eur J Heart Fail. 2017 Nov;19(11):1390-1400. doi: 10.1002/ejhf.933. Epub 2017 Aug 24. Eur J Heart Fail. 2017. PMID: 28836359 Free article. Review.
Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS. Bohula EA, et al. Among authors: verma s. Circulation. 2018 Jul 10;138(2):131-140. doi: 10.1161/CIRCULATIONAHA.118.034032. Epub 2018 Mar 12. Circulation. 2018. PMID: 29530884 Free article. Clinical Trial.
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B. Verma S, et al. Diabetologia. 2018 Aug;61(8):1712-1723. doi: 10.1007/s00125-018-4644-9. Epub 2018 May 19. Diabetologia. 2018. PMID: 29777264 Free PMC article. Clinical Trial.
6,437 results